Improving access to palliative care by enhancing primary care services in an upper middle-income country

Genomic profiling of penile squamous cell carcinoma reveals major biomarkers for efficacy of immunotherapy

Pembrolizumab shows notable antitumour activity for patients with high-risk non–muscle-invasive bladder cancer

Latest in PARP inhibitors and combination therapies for prostate cancer

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC

Plasma miR371 detects MRD and early relapse of germ cell tumours

Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low toxicity and good outcomes

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Nivolumab and salvage nivolumab plus ipilimumab for aRCC

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection